In November 2015, the Centers for Medicare and Medicaid Services issued a Medicaid Drug Rebate Notice on Assuring Medicaid Beneficiaries Access to Hepatitis C Drugs. States are in the process of responding to the notice and HIV/ID providers can play an important role in helping states develop clinically appropriate coverage policies.
In response to the harsh restrictions being placed on the new direct-acting antiviral (DAA) drugs by state Medicaid programs, the Centers for Medicare and Medicaid Services issued a program notice in Nov 2015 to remind states of Medicaid’s drug coverage rules. States are in the process of responding to the letter and ID/HIV providers can play an important role in helping Medicaid programs develop clinically appropriate coverage policies. This webinar provides tools and information to help providers become engaged in these discussions. The presenters have granted permission for their slides to be downloaded and used in presentations to educate other providers on these issues.
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States — Soumitri Barua; Robert Greenwald, JD; Jason Grebely, PhD; Gregory J. Dore, MBBS, PhD; Tracy Swan; and Lynn E. Taylor, MD, Ann Intern Med, Aug 4, 2015.
Nearly Half of Hepatitis C Patients on Medicaid Denied Coverage for Life-Saving Drugs, Penn Researchers Report – AASLD 2015 Liver Meeting (Asbstract LB-5), Vincent Lo Re III, MD, MSCE.
Assuring Medicaid Beneficiaries Access to Hepatitis C Drugs – Centers for Medicare and Medicaid Services, Medicaid Drug Rebate Notice, Nov. 5, 2015.